<!DOCTYPE html>
<html class="client-js"><head>
  <meta charset=UTF-8"UTF-8">
  <title>Interferon beta-1b</title>
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <script>
    function importScript() { return 1 } // this is to avoid the error from site.js
  </script>
  <link rel="canonical" href="https://en.wikipedia.org/wiki/Interferon_beta-1b">
  <link href="../-/s/css_modules/ext.cite.ux-enhancements.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/ext.cite.ux-enhancements.css" rel="stylesheet" type="text/css" class="">
<link href="../-/s/css_modules/ext.cite.styles.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/ext.cite.styles.css" rel="stylesheet" type="text/css" class="">
<link href="../-/s/css_modules/fi000001.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/skins.minerva.base.reset|skins.minerva.content.styles|ext.cite.style|site.styles|mobile.app.pagestyles.android|mediawiki.page.gallery.styles|mediawiki.skinning.content.parsoid.css" rel="stylesheet" type="text/css" class="">
  <link href="../-/s/css_modules/style.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/style.css" rel="stylesheet" type="text/css" class=""><link href="../-/s/css_modules/content.parsoid.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/content.parsoid.css" rel="stylesheet" type="text/css" class=""><link href="../-/s/css_modules/inserted_style.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/inserted_style.css" rel="stylesheet" type="text/css" class="">
  <script src="../-/j/js_modules/script.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/script.js" class=""></script><script src="../-/j/js_modules/masonry.min.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/masonry.min.js" class=""></script><script src="../-/j/js_modules/article_list_home.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/article_list_home.js" class=""></script><script src="../-/j/js_modules/images_loaded.min.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/images_loaded.min.js" class=""></script><script src="../-/j/js_modules/node_module/details-element-polyfill/dist/details-element-polyfill.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/node_module/details-element-polyfill/dist/details-element-polyfill.js" class=""></script>
<link type="root" href=""></head>

<body class="mediawiki mw-hide-empty-elt ns-0 ns-subject stable skin-minerva action-view animations">
  <div id="mw-mf-viewport" class="feature-header-v2">
    <div id="mw-mf-page-center">
      <div id="content" class="mw-body">
        <a id="top"></a>
        <div id="bodyContent" class="content mw-parser-output">
          
          <div id="mw-content-text" style="direction: ltr;"><h1 class="section-heading" tabindex="0" aria-haspopup="true" data-section-id="0">
  <span class="mw-headline" id="title_0">Interferon beta-1b</span>
</h1>
<div id="mf-section-0" class="mf-section-0" aria-pressed="true" aria-expanded="true">
  <p><b>Interferon beta-1b</b> is a cytokine in the interferon family used to treat the relapsing-remitting and secondary-progressive forms of multiple sclerosis (MS). It is approved for use after the first MS event. Closely related is interferon beta 1a, also indicated for MS, with a very similar drug profile.</p>

<table class="infobox" style="width:22em;border-spacing:2px;"><caption><span>Interferon beta-1b</span></caption><tbody><tr><th colspan="2" style="text-align:center;background:#ddd">Clinical data</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Trade names</th><td>Betaseron, Actoferon</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">AHFS/Drugs.com</th><td><span><a href="javascript:if(confirm('https://www.drugs.com/cons/interferon_beta-1b.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugs.com/cons/interferon_beta-1b.html'" tppabs="https://www.drugs.com/cons/interferon_beta-1b.html" class="external text external">Micromedex Detailed Consumer Information</a></span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">MedlinePlus</th><td><span><a href="javascript:if(confirm('https://medlineplus.gov/druginfo/meds/a601151.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://medlineplus.gov/druginfo/meds/a601151.html'" tppabs="https://medlineplus.gov/druginfo/meds/a601151.html" class="external text external">a601151</a></span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">License data</th><td><div class="plainlist">
<ul><li><small><abbr class="country-name">EU</abbr></small><span>&nbsp;</span>EMA:<span>&nbsp;</span><span><a href="javascript:if(confirm('http://www.ema.europa.eu/ema/index.jsp?curl=%2Fpages%2Fmedicines%2Flanding%2Fepar_search.jsp&mid=&searchTab=searchByKey&alreadyLoaded=true&isNewQuery=true&status=Authorised&status=Withdrawn&status=Suspended&status=Refused&keywordSearch=Submit&searchType=inn&taxonomyPath=&treeNumber=&searchGenericType=generics&keyword=Interferon+beta-1b  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.ema.europa.eu/ema/index.jsp?curl=%2Fpages%2Fmedicines%2Flanding%2Fepar_search.jsp&mid=&searchTab=searchByKey&alreadyLoaded=true&isNewQuery=true&status=Authorised&status=Withdrawn&status=Suspended&status=Refused&keywordSearch=Submit&searchType=inn&taxonomyPath=&treeNumber=&searchGenericType=generics&keyword=Interferon+beta-1b'" tppabs="http://www.ema.europa.eu/ema/index.jsp?curl=%2Fpages%2Fmedicines%2Flanding%2Fepar_search.jsp&mid=&searchTab=searchByKey&alreadyLoaded=true&isNewQuery=true&status=Authorised&status=Withdrawn&status=Suspended&status=Refused&keywordSearch=Submit&searchType=inn&taxonomyPath=&treeNumber=&searchGenericType=generics&keyword=Interferon+beta-1b" class="external text external">by INN</a></span></li></ul></div>
</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ATC code</th><td><div class="plainlist"><ul><li>L03AB08<span> </span>(<span><a href="javascript:if(confirm('https://www.whocc.no/atc_ddd_index/?code=L03AB08  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.whocc.no/atc_ddd_index/?code=L03AB08'" tppabs="https://www.whocc.no/atc_ddd_index/?code=L03AB08" class="external text external">WHO</a></span>)<span> </span></li></ul></div></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Legal status</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Legal status</th><td><div class="plainlist">
<ul><li>In<span>&nbsp;</span>general: ℞<span>&nbsp;</span>(Prescription only)</li></ul></div>
</td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Identifiers</th></tr><tr><td colspan="2" style="text-align:center"><div class="NavFrame collapsed" style="border: none; padding: 0;">
<div class="NavHead" style="font-size: 105%; background: transparent; text-align: left;">IUPAC name</div>
<ul class="NavContent" style="list-style: none none; margin-left: 0; word-break:break-all; text-align:left; padding-left:1.5em; text-indent:-1.5em; font-size: 105%; margin-top: 0; margin-bottom: 0; line-height: inherit;"><li style="line-height: inherit; margin: 0"><span style="font-size: 11px;">Human interferon beta</span></li></ul>
</div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">CAS Number</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('http://www.commonchemistry.org/ChemicalDetail.aspx?ref=145155-23-3  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.commonchemistry.org/ChemicalDetail.aspx?ref=145155-23-3'" tppabs="http://www.commonchemistry.org/ChemicalDetail.aspx?ref=145155-23-3" class="external text external">145155-23-3</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">IUPHAR/BPS</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8340  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8340'" tppabs="http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8340" class="external text external">8340</a></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">DrugBank</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.drugbank.ca/drugs/DB00068  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugbank.ca/drugs/DB00068'" tppabs="https://www.drugbank.ca/drugs/DB00068" class="external text external">DB00068</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ChemSpider</th><td><div class="plainlist"><ul><li>none</li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">UNII</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=TTD90R31WZ  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=TTD90R31WZ'" tppabs="https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=TTD90R31WZ" class="external text external">TTD90R31WZ</a></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">KEGG</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.kegg.jp/entry/D00746  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.kegg.jp/entry/D00746'" tppabs="https://www.kegg.jp/entry/D00746" class="external text external">D00746</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/X_mark.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/X_mark.svg.png" data-file-width="525" data-file-height="600" data-file-type="drawing" height="8" width="7"></span></figure-inline><span style="display:none">N</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ChEMBL</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/ChEMBL1201563  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/ChEMBL1201563'" tppabs="https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/ChEMBL1201563" class="external text external">ChEMBL1201563</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/X_mark.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/X_mark.svg.png" data-file-width="525" data-file-height="600" data-file-type="drawing" height="8" width="7"></span></figure-inline><span style="display:none">N</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;"><span>ECHA InfoCard</span></th><td><a href="javascript:if(confirm('https://echa.europa.eu/substance-information/-/substanceinfo/100.207.515  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://echa.europa.eu/substance-information/-/substanceinfo/100.207.515'" tppabs="https://echa.europa.eu/substance-information/-/substanceinfo/100.207.515" class="external text external">100.207.515</a> <figure-inline class="mw-valign-text-top"><img src="../I/m/OOjs_UI_icon_edit-ltr-progressive.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/OOjs_UI_icon_edit-ltr-progressive.svg.png" data-file-width="20" data-file-height="20" data-file-type="drawing" height="10" width="10"></figure-inline></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Chemical and physical data</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Formula</th><td><span>C</span><sub>908</sub><span>H</span><sub>1408</sub><span>N</span><sub>246</sub><span>O</span><sub>253</sub><span>S</span><sub>6</sub></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Molar mass</th><td><span class="nowrap">20<span style="margin-left:.25em;">011</span>.08</span><span>&nbsp;</span>g·mol<sup>−1</sup></td></tr><tr><td colspan="2" style="text-align:center"><style data-mw-deduplicate="TemplateStyles:r886047488">.mw-parser-output .nobold{font-weight:normal}</style><span class="nobold"><span>&nbsp;</span><sup><figure-inline><span><img src="../I/m/X_mark.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/X_mark.svg.png" data-file-width="525" data-file-height="600" data-file-type="drawing" height="8" width="7"></span></figure-inline><span style="display:none">N</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup><span>&nbsp;</span>(what is this?)</span><span class="nobold"><span>&nbsp;</span><span>&nbsp;</span><span class="reflink  nourlexpansion"><a href="javascript:if(confirm('https://en.wikipedia.org/w/index.php?title=Special:ComparePages&rev1=458271012&page2=Interferon+beta-1b  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://en.wikipedia.org/w/index.php?title=Special:ComparePages&rev1=458271012&page2=Interferon+beta-1b'" tppabs="https://en.wikipedia.org/w/index.php?title=Special:ComparePages&rev1=458271012&page2=Interferon+beta-1b" class="external text external">(verify)</a></span></span></td></tr></tbody></table>

</div><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Mechanism_of_action">Mechanism of action</h2></summary>
    
<p>Interferon beta balances the expression of pro- and anti-inflammatory agents in the brain, and reduces the number of inflammatory cells that cross the blood brain barrier.<span class="mw-ref" id="cite_ref-Kieseier_2011_1-0"><a href="#cite_note-Kieseier_2011-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span> Overall, therapy with interferon beta leads to a reduction of neuron inflammation.<span class="mw-ref" id="cite_ref-Kieseier_2011_1-1"><a href="#cite_note-Kieseier_2011-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span> Moreover, it is also thought to increase the production of nerve growth factor and consequently improve neuronal survival.<span class="mw-ref" id="cite_ref-Kieseier_2011_1-2"><a href="#cite_note-Kieseier_2011-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Side_effects">Side effects</h2></summary>
    
<div class="thumb tright"><div class="thumbinner" style="width:222px"><img src="../I/m/Implant.png" tppabs="https://ptable.com/wiki/compounds/I/m/Implant.png" data-file-width="2048" data-file-height="1536" data-file-type="bitmap" height="165" width="220"><div class="thumbcaption" style="text-align: left">Injectable medications can produce irritation or bruises at injection site. The bruise depicted was produced by a subcutaneous injection.</div></div></div>

<p>Interferon beta-1b is available only in injectable forms, and can cause skin reactions at the injection site that may include cutaneous necrosis. Skin reactions vary greatly in their clinical presentation.<span class="mw-ref" id="cite_ref-Walther_1999_2-0"><a href="#cite_note-Walther_1999-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span> They usually appear within the first month of treatment albeit their frequence and importance diminish after six months of treatment.<span class="mw-ref" id="cite_ref-Walther_1999_2-1"><a href="#cite_note-Walther_1999-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span> Skin reactions are more prevalent in women.<span class="mw-ref" id="cite_ref-Walther_1999_2-2"><a href="#cite_note-Walther_1999-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span> Mild skin reactions usually do not impede treatment whereas necroses appear in around 5% of patients and lead to the discontinuation of the therapy.<span class="mw-ref" id="cite_ref-Walther_1999_2-3"><a href="#cite_note-Walther_1999-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span> Also over time, a visible dent at the injection site due to the local destruction of fat tissue, known as lipoatrophy, may develop.</p>

<p>Interferons, a subclass of cytokines, are produced in the body during illnesses such as influenza in order to help fight the infection. They are responsible for many of the symptoms of influenza infections, including fever, muscle aches, fatigue, and headaches.<span class="mw-ref" id="cite_ref-Eccles_2005_3-0"><a href="#cite_note-Eccles_2005-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span> Many patients report influenza-like symptoms hours after taking interferon beta that usually improve within 24 hours, being such symptoms related to the temporary increase of cytokines.<span class="mw-ref" id="cite_ref-Walther_1999_2-4"><a href="#cite_note-Walther_1999-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span><span class="mw-ref" id="cite_ref-Compston_2008_4-0"><a href="#cite_note-Compston_2008-4" style="counter-reset: mw-Ref 4;"><span class="mw-reflink-text">[4]</span></a></span> This reaction tends to disappear after 3 months of treatment and its symptoms can be treated with over-the-counter nonsteroidal anti-inflammatory drugs, such as <a href="Ibuprofen.htm" tppabs="https://ptable.com/wiki/compounds/A/Ibuprofen" title="Ibuprofen">ibuprofen</a>, that reduce fever and pain.<span class="mw-ref" id="cite_ref-Walther_1999_2-5"><a href="#cite_note-Walther_1999-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span> Another common transient secondary effect with interferon-beta is a functional deterioration of already existing symptoms of the disease.<span class="mw-ref" id="cite_ref-Walther_1999_2-6"><a href="#cite_note-Walther_1999-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span> Such deterioration is similar to the one produced in MS patients due to heat, fever or stress (Uhthoff's phenomenon), usually appears within 24 hours of treatment, is more common in the initial months of treatment, and may last several days.<span class="mw-ref" id="cite_ref-Walther_1999_2-7"><a href="#cite_note-Walther_1999-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span> A symptom specially sensitive to worsening is spasticity.<span class="mw-ref" id="cite_ref-Walther_1999_2-8"><a href="#cite_note-Walther_1999-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span> Interferon-beta can also reduce numbers of white blood cells (leukopenia), lymphocytes (lymphopenia) and neutrophils (neutropenia), as well as affect liver function.<span class="mw-ref" id="cite_ref-Walther_1999_2-9"><a href="#cite_note-Walther_1999-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span> In most cases these effects are non-dangerous and reversible after cessation or reduction of treatment.<span class="mw-ref" id="cite_ref-Walther_1999_2-10"><a href="#cite_note-Walther_1999-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span> Nevertheless, recommendation is that all patients should be monitored through laboratory blood analyses, including liver function tests, to ensure safe use of interferons.<span class="mw-ref" id="cite_ref-Walther_1999_2-11"><a href="#cite_note-Walther_1999-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span></p>

<p>The injection-site reactions can be mitigated by rotating injection sites or by using one of the medications that requires less frequent injections.  Side effects are often onerous enough that many patients ultimately discontinue taking Interferons (or <a href="Glatiramer_acetate.htm" tppabs="https://ptable.com/wiki/compounds/A/Glatiramer_acetate" title="Glatiramer acetate">glatiramer acetate</a>, a comparable disease-modifying therapies requiring regular injections).</p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Efficacy">Efficacy</h2></summary>
    


    <details data-level="3" open="">
    <summary class="section-heading"><h3 id="Clinically_isolated_syndrome">Clinically isolated syndrome</h3></summary>
    
<p>The earliest clinical presentation of relapsing-remitting multiple sclerosis is the clinically isolated syndrome (CIS), that is, a single attack of a single symptom. During a CIS, there is a subacute attack suggestive of demyelination but the patient does not fulfill the criteria for diagnosis of multiple sclerosis.<span class="mw-ref" id="cite_ref-Miller_2005_5-0"><a href="#cite_note-Miller_2005-5" style="counter-reset: mw-Ref 5;"><span class="mw-reflink-text">[5]</span></a></span> Treatment with interferons after an initial attack decreases the risk of developing clinical definite MS.<span class="mw-ref" id="cite_ref-Compston_2008_4-1"><a href="#cite_note-Compston_2008-4" style="counter-reset: mw-Ref 4;"><span class="mw-reflink-text">[4]</span></a></span><span class="mw-ref" id="cite_ref-Bates_2011_6-0"><a href="#cite_note-Bates_2011-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Relapsing-remitting_MS">Relapsing-remitting MS</h3></summary>
    
<p>Medications are modestly effective at decreasing the number of attacks in relapsing-remitting multiple sclerosis<span class="mw-ref" id="cite_ref-7"><a href="#cite_note-7" style="counter-reset: mw-Ref 7;"><span class="mw-reflink-text">[7]</span></a></span> and in reducing the accumulation of brain lesions, which is measured using <a href="Gadolinium.htm" tppabs="https://ptable.com/wiki/compounds/A/Gadolinium" title="Gadolinium">gadolinium</a>-enhanced magnetic resonance imaging (MRI).<span class="mw-ref" id="cite_ref-Compston_2008_4-2"><a href="#cite_note-Compston_2008-4" style="counter-reset: mw-Ref 4;"><span class="mw-reflink-text">[4]</span></a></span> Interferons reduce relapses by approximately 30% and their safe profile make them the first-line treatments.<span class="mw-ref" id="cite_ref-Compston_2008_4-3"><a href="#cite_note-Compston_2008-4" style="counter-reset: mw-Ref 4;"><span class="mw-reflink-text">[4]</span></a></span> Nevertheless, not all the patients are responsive to these therapies. It is known that 30% of MS patients are non-responsive to Beta interferon.<span class="mw-ref" id="cite_ref-Bertolotto_2008_8-0"><a href="#cite_note-Bertolotto_2008-8" style="counter-reset: mw-Ref 8;"><span class="mw-reflink-text">[8]</span></a></span> They can be classified in genetic, pharmacological and pathogenetic non-responders.<span class="mw-ref" id="cite_ref-Bertolotto_2008_8-1"><a href="#cite_note-Bertolotto_2008-8" style="counter-reset: mw-Ref 8;"><span class="mw-reflink-text">[8]</span></a></span> One of the factors related to non-respondance is the presence of high levels of interferon beta neutralizing  antibodies. Interferon therapy, and specially interferon beta-1b, induces the production of  neutralizing  antibodies, usually in the second 6 months of treatment, in 5 to 30% of treated patients.<span class="mw-ref" id="cite_ref-Compston_2008_4-4"><a href="#cite_note-Compston_2008-4" style="counter-reset: mw-Ref 4;"><span class="mw-reflink-text">[4]</span></a></span> Moreover, a subset of RRMS patients with specially active MS, sometimes called "rapidly worsening MS" are normally non-responders to interferon beta-1b.<span class="mw-ref" id="cite_ref-9"><a href="#cite_note-9" style="counter-reset: mw-Ref 9;"><span class="mw-reflink-text">[9]</span></a></span><span class="mw-ref" id="cite_ref-10"><a href="#cite_note-10" style="counter-reset: mw-Ref 10;"><span class="mw-reflink-text">[10]</span></a></span></p>

<p>While more studies of the long-term effects of the drugs are needed,<span class="mw-ref" id="cite_ref-Compston_2008_4-5"><a href="#cite_note-Compston_2008-4" style="counter-reset: mw-Ref 4;"><span class="mw-reflink-text">[4]</span></a></span><span class="mw-ref" id="cite_ref-Freedman_2011_11-0"><a href="#cite_note-Freedman_2011-11" style="counter-reset: mw-Ref 11;"><span class="mw-reflink-text">[11]</span></a></span>  some data on the effects of interferons indicate that early-initiated long-term therapy is safe and it is related to better outcomes.<span class="mw-ref" id="cite_ref-Freedman_2011_11-1"><a href="#cite_note-Freedman_2011-11" style="counter-reset: mw-Ref 11;"><span class="mw-reflink-text">[11]</span></a></span>  More recent data suggest that interferon betas does not hasten disability.<span class="mw-ref" id="cite_ref-Shirani_2012_12-0"><a href="#cite_note-Shirani_2012-12" style="counter-reset: mw-Ref 12;"><span class="mw-reflink-text">[12]</span></a></span></p>

<p>Interferon-β exacerbates Th17-mediated inflammatory disease.<span class="mw-ref" id="cite_ref-Axtell_2011_13-0"><a href="#cite_note-Axtell_2011-13" style="counter-reset: mw-Ref 13;"><span class="mw-reflink-text">[13]</span></a></span></p>


</details>

</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Commercial_formulations">Commercial formulations</h2></summary>
    
<p>Betaferon/Betaseron is marketed today by Bayer Pharma. The <a href="javascript:if(confirm('https://en.wiktionary.org/wiki/originator  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://en.wiktionary.org/wiki/originator'" tppabs="https://en.wiktionary.org/wiki/originator" title="wikt:originator" class="external">originator</a> was Schering AG (Berlex in North America), now part of Bayer Pharms. Novartis has also introduced Extavia, a new brand of interferon beta-1b, in 2009.</p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="References">References</h2></summary>
    
<div class="reflist " style=" list-style-type: decimal;">
<div class="mw-references-wrap mw-references-columns"><ol class="mw-references references"><li id="cite_note-Kieseier_2011-1"> <span id="mw-reference-text-cite_note-Kieseier_2011-1" class="mw-reference-text"><cite id="CITEREFKieseier2011" class="citation journal cs1">Kieseier BC (June 2011). "The mechanism of action of interferon-β in relapsing multiple sclerosis". <i>CNS Drugs</i>. <b>25</b> (6): 491–502. doi:<a href="javascript:if(confirm('https://doi.org/10.2165%2F11591110-000000000-00000  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.2165%2F11591110-000000000-00000'" tppabs="https://doi.org/10.2165%2F11591110-000000000-00000" class="external text external">10.2165/11591110-000000000-00000</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/21649449  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/21649449'" tppabs="https://pubmed.ncbi.nlm.nih.gov/21649449" class="external text external">21649449</a>.</cite></span></li><li id="cite_note-Walther_1999-2"> <span id="mw-reference-text-cite_note-Walther_1999-2" class="mw-reference-text"><cite id="CITEREFWaltherHohlfeld1999" class="citation journal cs1">Walther EU, Hohlfeld R (November 1999). "Multiple sclerosis: side effects of interferon beta therapy and their management". <i>Neurology</i>. <b>53</b> (8): 1622–7. doi:<a href="javascript:if(confirm('https://doi.org/10.1212%2Fwnl.53.8.1622  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1212%2Fwnl.53.8.1622'" tppabs="https://doi.org/10.1212%2Fwnl.53.8.1622" class="external text external">10.1212/wnl.53.8.1622</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/10563602  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/10563602'" tppabs="https://pubmed.ncbi.nlm.nih.gov/10563602" class="external text external">10563602</a>.</cite></span></li><li id="cite_note-Eccles_2005-3"> <span id="mw-reference-text-cite_note-Eccles_2005-3" class="mw-reference-text"><cite id="CITEREFEccles2005" class="citation journal cs1">Eccles R (November 2005). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7185637  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7185637'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7185637" class="external text external">"Understanding the symptoms of the common cold and influenza"</a>. <i>The Lancet. Infectious Diseases</i>. <b>5</b> (11): 718–25. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2FS1473-3099%2805%2970270-X  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2FS1473-3099%2805%2970270-X'" tppabs="https://doi.org/10.1016%2FS1473-3099%2805%2970270-X" class="external text external">10.1016/S1473-3099(05)70270-X</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7185637  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7185637'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7185637" class="external text external">7185637</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/16253889  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/16253889'" tppabs="https://pubmed.ncbi.nlm.nih.gov/16253889" class="external text external">16253889</a>.</cite></span></li><li id="cite_note-Compston_2008-4"> <span id="mw-reference-text-cite_note-Compston_2008-4" class="mw-reference-text"><cite id="CITEREFCompstonColes2008" class="citation journal cs1">Compston A, Coles A (October 2008). "Multiple sclerosis". <i>Lancet</i>. <b>372</b> (9648): 1502–17. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2FS0140-6736%2808%2961620-7  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2FS0140-6736%2808%2961620-7'" tppabs="https://doi.org/10.1016%2FS0140-6736%2808%2961620-7" class="external text external">10.1016/S0140-6736(08)61620-7</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/18970977  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/18970977'" tppabs="https://pubmed.ncbi.nlm.nih.gov/18970977" class="external text external">18970977</a>.</cite></span></li><li id="cite_note-Miller_2005-5"> <span id="mw-reference-text-cite_note-Miller_2005-5" class="mw-reference-text"><cite id="CITEREFMillerBarkhofMontalbanThompson2005" class="citation journal cs1">Miller D, Barkhof F, Montalban X, Thompson A, Filippi M (May 2005). "Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis". <i>The Lancet. Neurology</i>. <b>4</b> (5): 281–8. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2FS1474-4422%2805%2970071-5  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2FS1474-4422%2805%2970071-5'" tppabs="https://doi.org/10.1016%2FS1474-4422%2805%2970071-5" class="external text external">10.1016/S1474-4422(05)70071-5</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/15847841  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/15847841'" tppabs="https://pubmed.ncbi.nlm.nih.gov/15847841" class="external text external">15847841</a>.</cite></span></li><li id="cite_note-Bates_2011-6"> <span id="mw-reference-text-cite_note-Bates_2011-6" class="mw-reference-text"><cite id="CITEREFBates2011" class="citation journal cs1">Bates D (January 2011). "Treatment effects of immunomodulatory therapies at different stages of multiple sclerosis in short-term trials". <i>Neurology</i>. <b>76</b> (1 Suppl 1): S14-25. doi:<a href="javascript:if(confirm('https://doi.org/10.1212%2FWNL.0b013e3182050388  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1212%2FWNL.0b013e3182050388'" tppabs="https://doi.org/10.1212%2FWNL.0b013e3182050388" class="external text external">10.1212/WNL.0b013e3182050388</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/21205678  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/21205678'" tppabs="https://pubmed.ncbi.nlm.nih.gov/21205678" class="external text external">21205678</a>.</cite></span></li><li id="cite_note-7"> <span id="mw-reference-text-cite_note-7" class="mw-reference-text"><cite id="CITEREFRiceIncorvaiaMunariEbers2001" class="citation journal cs1">Rice, G. P.; Incorvaia, B.; Munari, L.; Ebers, G.; Polman, C.; D'Amico, R.; Filippini, G. (2001). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7017973  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7017973'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7017973" class="external text external">"Interferon in relapsing-remitting multiple sclerosis"</a>. <i>The Cochrane Database of Systematic Reviews</i> (4): CD002002. doi:<a href="javascript:if(confirm('https://doi.org/10.1002%2F14651858.CD002002  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1002%2F14651858.CD002002'" tppabs="https://doi.org/10.1002%2F14651858.CD002002" class="external text external">10.1002/14651858.CD002002</a>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/1469-493X  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/1469-493X'" tppabs="https://www.worldcat.org/issn/1469-493X" class="external text external">1469-493X</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7017973  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7017973'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7017973" class="external text external">7017973</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/11687131  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/11687131'" tppabs="https://pubmed.ncbi.nlm.nih.gov/11687131" class="external text external">11687131</a>.</cite></span></li><li id="cite_note-Bertolotto_2008-8"> <span id="mw-reference-text-cite_note-Bertolotto_2008-8" class="mw-reference-text"><cite id="CITEREFBertolottoGilli2008" class="citation journal cs1">Bertolotto A, Gilli F (September 2008). "Interferon-beta responders and non-responders. A biological approach". <i>Neurological Sciences</i>. 29 Suppl 2: S216-7. doi:<a href="javascript:if(confirm('https://doi.org/10.1007%2Fs10072-008-0941-2  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1007%2Fs10072-008-0941-2'" tppabs="https://doi.org/10.1007%2Fs10072-008-0941-2" class="external text external">10.1007/s10072-008-0941-2</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/18690496  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/18690496'" tppabs="https://pubmed.ncbi.nlm.nih.gov/18690496" class="external text external">18690496</a>.</cite></span></li><li id="cite_note-9"> <span id="mw-reference-text-cite_note-9" class="mw-reference-text"><cite id="CITEREFButtinelliClemenziBorrielloDenaro2007" class="citation journal cs1">Buttinelli C, Clemenzi A, Borriello G, Denaro F, Pozzilli C, Fieschi C (November 2007). "Mitoxantrone treatment in multiple sclerosis: a 5-year clinical and MRI follow-up". <i>European Journal of Neurology</i>. <b>14</b> (11): 1281–7. doi:<a href="javascript:if(confirm('https://doi.org/10.1111%2Fj.1468-1331.2007.01969.x  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1111%2Fj.1468-1331.2007.01969.x'" tppabs="https://doi.org/10.1111%2Fj.1468-1331.2007.01969.x" class="external text external">10.1111/j.1468-1331.2007.01969.x</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/17956449  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/17956449'" tppabs="https://pubmed.ncbi.nlm.nih.gov/17956449" class="external text external">17956449</a>.</cite></span></li><li id="cite_note-10"> <span id="mw-reference-text-cite_note-10" class="mw-reference-text"><cite id="CITEREFBosterEdanFrohmanJaved2008" class="citation journal cs1">Boster A, Edan G, Frohman E, Javed A, Stuve O, Tselis A, Weiner H, Weinstock-Guttman B, Khan O (February 2008). "Intense immunosuppression in patients with rapidly worsening multiple sclerosis: treatment guidelines for the clinician". <i>The Lancet. Neurology</i>. <b>7</b> (2): 173–83. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2FS1474-4422%2808%2970020-6  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2FS1474-4422%2808%2970020-6'" tppabs="https://doi.org/10.1016%2FS1474-4422%2808%2970020-6" class="external text external">10.1016/S1474-4422(08)70020-6</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/18207115  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/18207115'" tppabs="https://pubmed.ncbi.nlm.nih.gov/18207115" class="external text external">18207115</a>.</cite></span></li><li id="cite_note-Freedman_2011-11"> <span id="mw-reference-text-cite_note-Freedman_2011-11" class="mw-reference-text"><cite id="CITEREFFreedman2011" class="citation journal cs1">Freedman MS (January 2011). "Long-term follow-up of clinical trials of multiple sclerosis therapies". <i>Neurology</i>. <b>76</b> (1 Suppl 1): S26-34. doi:<a href="javascript:if(confirm('https://doi.org/10.1212%2FWNL.0b013e318205051d  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1212%2FWNL.0b013e318205051d'" tppabs="https://doi.org/10.1212%2FWNL.0b013e318205051d" class="external text external">10.1212/WNL.0b013e318205051d</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/21205679  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/21205679'" tppabs="https://pubmed.ncbi.nlm.nih.gov/21205679" class="external text external">21205679</a>.</cite></span></li><li id="cite_note-Shirani_2012-12"> <span id="mw-reference-text-cite_note-Shirani_2012-12" class="mw-reference-text"><cite id="CITEREFShiraniZhaoKarimEvans2012" class="citation journal cs1">Shirani A, Zhao Y, Karim ME, Evans C, Kingwell E, van der Kop ML, Oger J, Gustafson P, Petkau J, Tremlett H (2012). <a href="javascript:if(confirm('https://doi.org/10.1001/jama.2012.7625  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1001/jama.2012.7625'" tppabs="https://doi.org/10.1001/jama.2012.7625" class="external text external">"Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis"</a>. <i>JAMA</i>. <b>308</b> (3): 247–56. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.1001%2Fjama.2012.7625  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1001%2Fjama.2012.7625'" tppabs="https://doi.org/10.1001%2Fjama.2012.7625" class="external text external">10.1001/jama.2012.7625</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/22797642  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/22797642'" tppabs="https://pubmed.ncbi.nlm.nih.gov/22797642" class="external text external">22797642</a>.</cite></span></li><li id="cite_note-Axtell_2011-13"> <span id="mw-reference-text-cite_note-Axtell_2011-13" class="mw-reference-text"><cite id="CITEREFAxtellRamanSteinman2011" class="citation journal cs1">Axtell RC, Raman C, Steinman L (June 2011). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5414634  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5414634'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5414634" class="external text external">"Interferon-β exacerbates Th17-mediated inflammatory disease"</a>. <i>Trends in Immunology</i>. <b>32</b> (6): 272–7. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.it.2011.03.008  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.it.2011.03.008'" tppabs="https://doi.org/10.1016%2Fj.it.2011.03.008" class="external text external">10.1016/j.it.2011.03.008</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5414634  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5414634'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5414634" class="external text external">5414634</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/21530402  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/21530402'" tppabs="https://pubmed.ncbi.nlm.nih.gov/21530402" class="external text external">21530402</a>.</cite></span></li></ol></div></div>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="External_links">External links</h2></summary>
    
<ul><li><cite class="citation web cs1"><a href="javascript:if(confirm('https://druginfo.nlm.nih.gov/drugportal/name/interferon%20beta-1b  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://druginfo.nlm.nih.gov/drugportal/name/interferon%20beta-1b'" tppabs="https://druginfo.nlm.nih.gov/drugportal/name/interferon%20beta-1b" class="external text external">"Interferon beta-1b"</a>. <i>Drug Information Portal</i>. U.S. National Library of Medicine.</cite></li></ul>

<div role="navigation" class="navbox" aria-labelledby="Cell_signaling:_cytokines" style="padding:3px"><table class="nowraplinks mw-collapsible mw-collapsed navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><div id="Cell_signaling:_cytokines" style="font-size:114%;margin:0 4em">Cell signaling: cytokines</div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%">By family</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%">Chemokine</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%">CCL</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>CCL1</li>
<li>CCL2/MCP1</li>
<li>CCL3/MIP1α</li>
<li>CCL4/MIP1β</li>
<li>CCL5/RANTES</li>
<li>CCL6</li>
<li>CCL7</li>
<li>CCL8</li>
<li>CCL9</li>
<li>CCL11</li>
<li>CCL12</li>
<li>CCL13</li>
<li>CCL14</li>
<li>CCL15</li>
<li>CCL16</li>
<li>CCL17</li>
<li>CCL18/PARC/DCCK1/AMAC1/MIP4</li>
<li>CCL19</li>
<li>CCL20</li>
<li>CCL21</li>
<li>CCL22</li>
<li>CCL23</li>
<li>CCL24</li>
<li>CCL25</li>
<li>CCL26</li>
<li>CCL27</li>
<li>CCL28</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">CXCL</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>CXCL1/KC</li>
<li>CXCL2</li>
<li>CXCL3</li>
<li>CXCL4</li>
<li>CXCL5</li>
<li>CXCL6</li>
<li>CXCL7</li>
<li>CXCL8/IL8</li>
<li>CXCL9</li>
<li>CXCL10</li>
<li>CXCL11</li>
<li>CXCL12</li>
<li>CXCL13</li>
<li>CXCL14</li>
<li>CXCL15</li>
<li>CXCL16</li>
<li>CXCL17</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">CX3CL</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>CX3CL1</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">XCL</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>XCL1</li>
<li>XCL2</li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%"><a href="Tumor_necrosis_factors.htm" tppabs="https://ptable.com/wiki/compounds/A/Tumor_necrosis_factors" title="Tumor necrosis factors" class="mw-redirect">TNF</a></th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>TNFA</li>
<li>Lymphotoxin
<ul><li>TNFB/LTA</li>
<li>TNFC/LTB</li></ul></li>
<li>TNFSF4</li>
<li>TNFSF5/CD40LG</li>
<li>TNFSF6</li>
<li>TNFSF7</li>
<li>TNFSF8</li>
<li>TNFSF9</li>
<li>TNFSF10</li>
<li>TNFSF11</li>
<li>TNFSF13</li>
<li>TNFSF13B</li>
<li>EDA</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Interleukin</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%">Type I<br>(grouped by<br>receptor<br>subunit)</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%">γ chain</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Interleukin_2.htm" tppabs="https://ptable.com/wiki/compounds/A/Interleukin_2" title="Interleukin 2">IL2</a>/IL15</li>
<li>IL4/IL13</li>
<li>IL7</li>
<li>IL9</li>
<li>IL21</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">β chain</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>IL3</li>
<li>IL5</li>
<li>GMCSF</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">IL6 like/gp130</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>IL6</li>
<li>IL11</li>
<li>IL27</li>
<li>IL30</li>
<li>IL31
<ul><li>+non IL OSM</li>
<li>LIF</li>
<li>CNTF</li>
<li>CTF1</li></ul></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%"><span class="new">IL12 family</span>/IL12RB1</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>IL12</li>
<li>IL23</li>
<li>IL27</li>
<li>IL35</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Other</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>IL14</li>
<li>IL16</li>
<li>IL32</li>
<li>IL34</li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Type II</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%">IL10 family</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>IL10/IL22</li>
<li>IL19</li>
<li>IL20</li>
<li>IL24</li>
<li>IL26</li>
<li>Interferon type III
<ul><li>IL28/IFNL2+3</li>
<li>IL29/IFNL1</li></ul></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Interferon</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%">I</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>IFNA1</li>
<li>IFNA2</li>
<li>IFNA4</li>
<li>IFNA5</li>
<li>IFNA6</li>
<li>IFNA7</li>
<li>IFNA8</li>
<li>IFNA10</li>
<li>IFNA13</li>
<li>IFNA14</li>
<li>IFNA16</li>
<li>IFNA17</li>
<li>IFNA21</li>
<li>IFNB1</li>
<li>IFNK</li>
<li>IFNW1</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">II</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>IFNG</li></ul>
</div></td></tr></tbody></table><div></div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Ig superfamily</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>IL1 family: IL1A/IL1F1</li>
<li>IL1B/IL1F2</li>
<li>1Ra/IL1F3</li>
<li>IL1F5</li>
<li>IL1F6</li>
<li>IL1F7</li>
<li>IL1F8</li>
<li>IL1F9</li>
<li>IL1F10</li>
<li>33/IL1F11</li>
<li>18/IL1G</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">IL17 family</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>IL17/IL25 (IL17A)</li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Other</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Hematopoietic
<ul><li>KITLG</li>
<li>Colony-stimulating factor</li></ul></li>
<li>SPP1</li>
<li>MIF</li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">By function/<br>cell</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>proinflammatory cytokine</i>
<ul><li>IL1</li>
<li>TNFA</li></ul></li></ul>

<ul><li>Monokine</li>
<li>Lymphokine
<ul><li><i>T<sub>h</sub>1</i>
<ul><li>IFNγ</li>
<li>TNFβ</li></ul></li>
<li><i>T<sub>h</sub>2</i>
<ul><li>IL4</li>
<li>IL5</li>
<li>IL6</li>
<li>IL10</li>
<li>IL13</li></ul></li></ul></li></ul>
</div></td></tr></tbody></table></div>
<div role="navigation" class="navbox" aria-labelledby="Immunostimulants_(L03)" style="padding:3px"><table class="nowraplinks hlist mw-collapsible autocollapse navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><div id="Immunostimulants_(L03)" style="font-size:114%;margin:0 4em">Immunostimulants (L03)</div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%">Endogenous</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%">Cytokines</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%">Colony-stimulating factors</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>G-CSF
<ul><li><a href="Filgrastim.htm" tppabs="https://ptable.com/wiki/compounds/A/Filgrastim" title="Filgrastim">Filgrastim</a> / Lipegfilgrastim / <a href="Pegfilgrastim.htm" tppabs="https://ptable.com/wiki/compounds/A/Pegfilgrastim" title="Pegfilgrastim">Pegfilgrastim</a></li>
<li>Lenograstim</li>
<li><i>Eflapegrastim</i></li></ul></li>
<li>GM-CSF
<ul><li>Molgramostim</li>
<li><a href="Sargramostim.htm" tppabs="https://ptable.com/wiki/compounds/A/Sargramostim" title="Sargramostim">Sargramostim</a></li></ul></li>
<li>SCF
<ul><li>Ancestim</li></ul></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Interferons</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>alpha</i>:
<ul><li>Albinterferon</li>
<li>Interferon alfa natural</li>
<li><span class="new">Interferon alfa 2a</span> / Peginterferon alfa-2a</li>
<li>Interferon alfa 2b / Peginterferon alfa-2b</li>
<li><span class="new">Interferon alfa n1</span></li>
<li><a href="Interferon_alfacon-1.htm" tppabs="https://ptable.com/wiki/compounds/A/Interferon_alfacon-1" title="Interferon alfacon-1">Interferon alfacon-1</a></li>
<li>Interferon alpha-n3</li></ul></li>
<li><i>beta</i>:
<ul><li>Interferon beta natural</li>
<li>Interferon beta 1a</li>
<li>Interferon beta 1b</li></ul></li>
<li>Interferon gamma</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Interleukins</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Interleukin_2.htm" tppabs="https://ptable.com/wiki/compounds/A/Interleukin_2" title="Interleukin 2">Aldesleukin</a></li>
<li><a href="Oprelvekin.htm" tppabs="https://ptable.com/wiki/compounds/A/Oprelvekin" title="Oprelvekin">Oprelvekin</a></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Other protein / peptide</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Growth_hormone.htm" tppabs="https://ptable.com/wiki/compounds/A/Growth_hormone" title="Growth hormone">Growth hormone</a></li>
<li>Immunocyanin</li>
<li><a href="Adenosine_deaminase.htm" tppabs="https://ptable.com/wiki/compounds/A/Pegademase" title="Pegademase" class="mw-redirect">Pegademase</a></li>
<li>Prolactin</li>
<li>Tasonermin</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Other</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Female sex steroids</li>
<li><a href="Histamine_dihydrochloride.htm" tppabs="https://ptable.com/wiki/compounds/A/Histamine_dihydrochloride" title="Histamine dihydrochloride">Histamine dihydrochloride</a></li>
<li>Poly ICLC</li>
<li><a href="Vitamin_D.htm" tppabs="https://ptable.com/wiki/compounds/A/Vitamin_D" title="Vitamin D">Vitamin D</a></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Exogenous</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>beta-glucan
<ul><li>Lentinan</li></ul></li>
<li>heterocyclic compound
<ul><li>Plerixafor</li></ul></li>
<li><a href="8-Hydroxyquinoline.htm" tppabs="https://ptable.com/wiki/compounds/A/8-Hydroxyquinoline" title="8-Hydroxyquinoline">hydroxyquinoline</a>
<ul><li>Roquinimex</li></ul></li>
<li>Mifamurtide</li>
<li>oligopeptides
<ul><li><a href="Glatiramer_acetate.htm" tppabs="https://ptable.com/wiki/compounds/A/Glatiramer_acetate" title="Glatiramer acetate">Glatiramer acetate</a></li>
<li>Thymopentin</li>
<li>Thymosin α1</li>
<li>Thymulin</li></ul></li>
<li>polyribonucleotide
<ul><li>Polyinosinic:polycytidylic acid</li></ul></li>
<li><a href="Thiazolidine.htm" tppabs="https://ptable.com/wiki/compounds/A/Thiazolidine" title="Thiazolidine">thiazolidine</a>
<ul><li><a href="Pidotimod.htm" tppabs="https://ptable.com/wiki/compounds/A/Pidotimod" title="Pidotimod">Pidotimod</a></li></ul></li>
<li>vaccines
<ul><li>Bacillus Calmette–Guérin</li>
<li>Melanoma vaccine</li>
<li>Sipuleucel-T</li></ul></li></ul>
</div></td></tr></tbody></table></div>
<div role="navigation" class="navbox" aria-labelledby="Cytokine_receptor_modulators" style="padding:3px"><table class="nowraplinks hlist mw-collapsible mw-collapsed navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><div id="Cytokine_receptor_modulators" style="font-size:114%;margin:0 4em">Cytokine receptor modulators</div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Chemokine</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>See here instead.</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">CSF</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Erythropoietin</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> <span class="new">ARA-290</span></li>
<li><span class="new">Asialo erythropoietin</span></li>
<li><span class="new">Carbamylated erythropoietin</span></li>
<li><span class="new">CNTO-530</span></li>
<li><a href="Darbepoetin_alfa.htm" tppabs="https://ptable.com/wiki/compounds/A/Darbepoetin_alfa" title="Darbepoetin alfa">Darbepoetin alfa</a></li>
<li><a href="Epoetin_alfa.htm" tppabs="https://ptable.com/wiki/compounds/A/Epoetin_alfa" title="Epoetin alfa">Epoetin alfa</a></li>
<li>Epoetin beta</li>
<li><span class="new">Epoetin delta</span></li>
<li><span class="new">Epoetin epsilon</span></li>
<li><span class="new">Epoetin gamma</span></li>
<li><span class="new">Epoetin kappa</span></li>
<li><span class="new">Epoetin omega</span></li>
<li><span class="new">Epoetin theta</span></li>
<li>Epoetin zeta</li>
<li>Erythropoietin (EPO)</li>
<li><span class="new">Erythropoietin-Fc</span></li>
<li>Methoxy polyethylene glycol-epoetin beta (CERA/Mircera)</li>
<li>Peginesatide</li>
<li><span class="new">Pegol sihematide (EPO-018B)</span></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">G-CSF (CSF3)</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> <a href="Filgrastim.htm" tppabs="https://ptable.com/wiki/compounds/A/Filgrastim" title="Filgrastim">Filgrastim</a></li>
<li>Granulocyte colony-stimulating factor</li>
<li>Lenograstim</li>
<li><span class="new">Leridistim</span></li>
<li>Lipegfilgrastim</li>
<li><span class="new">Nartograstim</span></li>
<li><a href="Pegfilgrastim.htm" tppabs="https://ptable.com/wiki/compounds/A/Pegfilgrastim" title="Pegfilgrastim">Pegfilgrastim</a></li>
<li><span class="new">Pegnartograstim</span></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">GM-CSF (CSF2)</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> <span class="new">Ecogramostim</span></li>
<li>Granulocyte macrophage colony-stimulating factor</li>
<li><span class="new">Milodistim</span></li>
<li>Molgramostim</li>
<li><span class="new">Regramostim</span></li>
<li><a href="Sargramostim.htm" tppabs="https://ptable.com/wiki/compounds/A/Sargramostim" title="Sargramostim">Sargramostim</a></li></ul>

<ul><li><i>Antibodies:</i> Mavrilimumab</li>
<li>Namilumab</li>
<li>Otilimab</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">M-CSF (CSF1)</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> <span class="new">Cilmostim</span></li>
<li>Interleukin-34</li>
<li><span class="new">Lanimostim</span></li>
<li>Macrophage colony-stimulating factor</li>
<li><span class="new">Mirimostim</span></li></ul>

<ul><li><i>Kinase inhibitors:</i> <span class="new">Agerafenib</span></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">SCF (c-Kit)</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>See here instead.</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Thrombopoietin</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Eltrombopag</li>
<li><span class="new">Pegacaristim</span></li>
<li>Promegapoietin</li>
<li>Romiplostim</li>
<li>Thrombopoietin (THPO, MGDF)</li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Interferon</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">IFNAR (α/β, I)</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Albinterferon</li>
<li>Interferon alpha (interferon alfa, IFN-α)</li>
<li>Interferon alfa (IFNA1, IFNA2, IFNA4, IFNA5, IFNA6, IFNA7, IFNA8, IFNA10, IFNA13, IFNA14, IFNA16, IFNA17, IFNA21)</li>
<li><span class="new">Interferon alfa 2a</span></li>
<li>Interferon alfa 2b</li>
<li><span class="new">Interferon alfa n1</span></li>
<li><a href="Interferon_alfacon-1.htm" tppabs="https://ptable.com/wiki/compounds/A/Interferon_alfacon-1" title="Interferon alfacon-1">Interferon alfacon-1</a></li>
<li>Interferon alpha-n3</li>
<li>Interferon beta (IFN-β) (IFNB1, <span class="new">IFNB3</span>)</li>
<li>Interferon beta 1a</li>
<li>Interferon beta 1b</li>
<li>Interferon kappa (IFN-ε/κ/τ/ζ, IFNK)</li>
<li>Interferon omega (IFN-ω, IFNW1)</li>
<li>Peginterferon alfa-2a</li>
<li>Peginterferon alfa-2b</li></ul>

<ul><li><i>Antibodies:</i> Anifrolumab</li>
<li>Faralimomab</li>
<li><span class="new">MEDI-545</span></li>
<li>Rontalizumab</li>
<li>Sifalimumab</li></ul>

<ul><li><i>Decoy receptors:</i> <span class="new">Bifarcept</span></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">IFNGR (γ, II)</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Interferon gamma (IFN-γ)</li>
<li><span class="new">Interferon gamma 1b</span></li></ul>

<ul><li><i>Antibodies:</i> Emapalumab</li>
<li>Fontolizumab</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">IFNLR (λ, III)</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>See IL-28R (IFNLR) here instead.</li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Interleukin</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>See here instead.</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">TGFβ</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>See here instead.</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">TNF</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>See here instead.</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Others</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">JAK<br><small>(inhibitors)</small></th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">JAK1</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Baricitinib</li>
<li>Filgotinib</li>
<li>Momelotinib</li>
<li>Oclacitinib</li>
<li>Ruxolitinib</li>
<li>Tofacitinib (tasocitinib, CP-690550)</li>
<li>Upadacitinib</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">JAK2</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><span class="new">AG-490</span></li>
<li>Atiprimod</li>
<li><span class="new">AZD-1480</span></li>
<li>Baricitinib</li>
<li><span class="new">CHZ868</span></li>
<li>Cucurbitacin I (elatericin B, JSI-124)</li>
<li>CYT387</li>
<li>Lestaurtinib</li>
<li><span class="new">NSC-7908</span></li>
<li><span class="new">NSC-33994</span></li>
<li>Pacritinib</li>
<li>Ruxolitinib</li>
<li><span class="new">SD-1008</span></li>
<li>Tofacitinib (tasocitinib, CP-690550)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">JAK3</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><span class="new">AG-490</span></li>
<li><span class="new">Cercosporamide</span></li>
<li>Decernotinib (VX-509)</li>
<li><span class="new">TCS-21311</span></li>
<li>Tofacitinib (tasocitinib, CP-690550)</li>
<li><span class="new">WHI-P 154</span></li>
<li><span class="new">ZM-39923</span></li>
<li><span class="new">ZM-449829</span></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Others</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Additional cytokines:</i> Cardiotrophin 1 (CT-1)</li>
<li>FMS-like tyrosine kinase 3 ligand (FLT3L)</li>
<li>Leukemia/leukocyte inhibitory factor (LIF)</li>
<li>Oncostatin M (OSM)</li>
<li>Thymic stromal lymphopoietin (TSLP)</li></ul>

<ul><li><i>Additional cytokine receptor modulators:</i> <span class="new">Emfilermin</span></li>
<li>Lestaurtinib</li>
<li>Midostaurin</li>
<li>Quizartinib</li>
<li><a href="Sorafenib.htm" tppabs="https://ptable.com/wiki/compounds/A/Sorafenib" title="Sorafenib">Sorafenib</a></li>
<li><a href="Sunitinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Sunitinib" title="Sunitinib">Sunitinib</a></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><td class="navbox-abovebelow" colspan="2"><div>
<dl><dt>See also</dt>
<dd><i>Receptor/signaling modulators</i></dd>
<dd><i>Signaling peptide/protein receptor modulators</i></dd>
<dd><i>Growth factor receptor modulators</i></dd></dl>
</div></td></tr></tbody></table></div>




<style data-mw-deduplicate="TemplateStyles:r951705291">.mw-parser-output cite.citation{font-style:inherit}.mw-parser-output .citation q{quotes:"\"""\"""'""'"}.mw-parser-output .id-lock-free a,.mw-parser-output .citation .cs1-lock-free a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .id-lock-limited a,.mw-parser-output .id-lock-registration a,.mw-parser-output .citation .cs1-lock-limited a,.mw-parser-output .citation .cs1-lock-registration a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .id-lock-subscription a,.mw-parser-output .citation .cs1-lock-subscription a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration{color:#555}.mw-parser-output .cs1-subscription span,.mw-parser-output .cs1-registration span{border-bottom:1px dotted;cursor:help}.mw-parser-output .cs1-ws-icon a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/4/4c/Wikisource-logo.svg/12px-Wikisource-logo.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/4/4c/Wikisource-logo.svg/12px-Wikisource-logo.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg*/);background-repeat:no-repeat;background-size:12px;background-position:right .1em center}.mw-parser-output code.cs1-code{color:inherit;background:inherit;border:inherit;padding:inherit}.mw-parser-output .cs1-hidden-error{display:none;font-size:100%}.mw-parser-output .cs1-visible-error{font-size:100%}.mw-parser-output .cs1-maint{display:none;color:#33aa33;margin-left:0.3em}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration,.mw-parser-output .cs1-format{font-size:95%}.mw-parser-output .cs1-kern-left,.mw-parser-output .cs1-kern-wl-left{padding-left:0.2em}.mw-parser-output .cs1-kern-right,.mw-parser-output .cs1-kern-wl-right{padding-right:0.2em}.mw-parser-output .citation .mw-selflink{font-weight:inherit}</style>
    
</details><!--htdig_noindex--><div><div style="clear:both; background-image:linear-gradient(180deg, #E8E8E8, white); border-top: dashed 2px #AAAAAA; padding: 0.5em 0.5em 0.5em 0.5em; margin-top: 1em; direction: ltr;">
    This article is issued from <a class="external text" title="Last edited on 2020-08-02" href="javascript:if(confirm('https://en.wikipedia.org/wiki/?title=Interferon_beta-1b&oldid=970717583  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://en.wikipedia.org/wiki/?title=Interferon_beta-1b&oldid=970717583'" tppabs="https://en.wikipedia.org/wiki/?title=Interferon_beta-1b&oldid=970717583">Wikipedia</a>. The text is licensed under <a class="external text" href="javascript:if(confirm('https://creativecommons.org/licenses/by-sa/4.0/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://creativecommons.org/licenses/by-sa/4.0/'" tppabs="https://creativecommons.org/licenses/by-sa/4.0/">Creative Commons - Attribution - Sharealike</a>. Additional terms may apply for the media files.
</div>
</div><!--/htdig_noindex--></div>
        </div>
      </div>
    </div>
  </div>
  <script src="../-/j/js_modules/jsConfigVars.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/jsConfigVars.js" class=""></script>
  <script src="../-/j/js_modules/startup.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/startup.js" class=""></script>
<script src="../-/j/js_modules/jquery.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/jquery.js" class=""></script>
<script src="../-/j/js_modules/mediawiki.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/mediawiki.js" class=""></script>
<script src="../-/j/js_modules/site.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/site.js" class=""></script>
<script src="../-/j/js_modules/ext.cite.ux-enhancements.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/ext.cite.ux-enhancements.js" class=""></script>



</body></html>